COVID-19 mRNA vaccines and the deep-freeze barrier (2020-2021)
Pfizer's mRNA vaccine required storage near -70°C, far colder than standard freezers. Hospitals needed dedicated freezers or dry ice, and rural and low-income regions struggled to deploy doses quickly.
Cold-chain logistics managed the rollout, but distribution was uneven and doses were lost to temperature failures.
The episode showed how ultra-cold storage limits equitable access to biologic medicines.
BoSS targets the same constraint, the cold chain, for living cell therapies, which are far harder to stabilize than a frozen vaccine.
